Fox Chase Cancer Center

This early-phase study tests a combination of low-dose radiation and a drug called 5-aminolevulinic acid (ALA) for people with advanced solid tumors that have stopped responding to standard treatments. ALA is thought to collect in cancer cells and make them more sensitive to radi…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and anti-angiogenic therapy can help people with advanced non-squamous lung cancer who either have a specific EGFR mutation or have never smoked. About 107 participants will receive eithe…

This early-phase study tests whether a combination of three drugs (paricalcitol, hydroxychloroquine, and losartan) can safely modify the supportive tissue around pancreatic tumors before surgery. About 20 adults with resectable pancreatic cancer will take these drugs for at least…

This study tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The goal is to see if this gentler radiation, given with the chemotherapy drug gemcitabine, causes fewer side effects than standard rad…

This study tests a two-drug chemotherapy plan (alternating FOLFOX and FOLFIRI) in adults aged 65 and older with newly diagnosed metastatic pancreatic cancer. The goal is to see if this approach causes fewer side effects than the standard three-drug regimen, while still controllin…

This study tests a combination of two drugs, nivolumab and ramucirumab, in people with advanced non-small cell lung cancer that has returned or spread. Participants must have already received immunotherapy. The main goal is to see if the combination can control the disease, meani…

This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The first part finds the safest dose, and the second part checks how well the drugs shrink tumors. About 98 participants, both previously treated and untreated, are enrolle…

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with cancer that has spread will receive the drug alone or with pembrolizumab. The goal is to see if a de-escalated schedu…

This study looks at tumor samples from 15 people with kidney or bladder cancer whose cancer came back after immunotherapy. Researchers compare the genes and structure of the original tumor with the new growth to find clues about why the cancer became resistant. The goal is to bet…